Breaking News

GSK Discontinues Development of Anacor Drug

October 5, 2012

Returns all rights, amends R&D pact

GlaxoSmithKline has discontinued development of GSK2251052 following a recent clinical trial that was stopped due to the identification of microbiological findings of resistance in a small number of patients undergoing treatment of complicated urinary tract infections (cUTI). GSK has decided to discontinue further development of GSK2251052 and return all rights to Anacor.
 
Anacor Pharmaceuticals licensed the drug to GSK in July 2010 under an ongoing R&D collaboration. GSK is continuing to fund Anacor’s research activities in tuberculosis as under the companies’ amended R&D collaboration.

Related Contract Manufacturing:

  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus